NeuroPace Inc (NPCE) Form 10-Q — Aug 11, 2026

$NPCEForm 10-QFiled Aug 11, 2026, 4:33 PM ET0001528287-26-000030Original filing

NeuroPace reported Q2 2026 revenue of $22.8 million, up 17% year over year, and cut its net loss 28% to $6.2 million (-$0.18 per share) from $8.7 million a year earlier, with the continuing-operations loss down 38%. Six-month revenue rose 19% to $44.8 million on higher RNS System initial implants and replacements. The key negative is regulatory: on July 28, 2026 the FDA notified NeuroPace that its PMA-S to expand the RNS System label to drug-resistant idiopathic generalized epilepsy is not approvable in its current form and requested additional information.

Key figures

Eps: -$0.18 (Q2 2026 basic and diluted)
Revenue: $22.8 million (Q2 2026)
Net Income: -$6.2 million (Q2 2026 net loss, vs -$8.7 million year-ago)
Total Debt: $59.0 million (MidCap Term Loan, net of debt discount and issuance costs)
Revenue Yoy: +17% (Q2 2026 vs Q2 2025); +19% for six months ended June 30, 2026
Total Assets: $97.0 million (June 30, 2026)
Cash Position: $51.7 million (cash, cash equivalents and short-term investments at June 30, 2026)
Shares Outstanding: 34324274
Revolver: $15.0 million undrawn
Six month net loss: -$12.9 million vs -$15.2 million year-ago
Accumulated deficit: $565.3 million
Future debt payments: $83.9 million total principal, exit fee and interest through maturity
Gross margin q2 2026: 82.8% (vs 83.1% year-ago)
Ttm rns system revenue: $89.2 million vs $72.8 million covenant minimum
Effective interest rate: 10.7% at June 30, 2026
Midcap term loan facility: $60.0 million funded June 2025; matures June 4, 2030
H1 2026 operating cash use: $9.8 million
Loss from continuing operations q2: -$6.2 million vs -$10.0 million year-ago (38% improvement)

Price after filing

1 day: +0.3%7 days: -2.4%30 days: -2.2%

Close on the filing date to close N calendar days later (from $14.83). Historical, not a forecast.

AI analysis

Red flags6 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.